CYFWY yields 12.38% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, CYFWY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYFWY + PFE for your $10,000?
Cyfrowy Polsat S.A. provides digital satellite platform and terrestrial television (TV), and telecommunication services in Poland. The company offers satellite and Internet pay television, mobile and fixed-line telephony, mobile and fixed-line broadband Internet access, wholesale, and TV broadcasting and production services, as well as online content, news, and video sharing services. It offers approximately 150 TV channels, including terrestrial, general entertainment, sports and e-sports, music, lifestyle, news/information, children's, education, and movie channels; and over the top services, such as Cyfrowy Polsat GO, VOD/PPV, online video and music, catch-up TV, and multiroom HD services. In addition, the company provides database of legal video content and live broadcasts; online TV channels; live coverages of sports events; and feature films, and TV series and programs. Further, it offers telecommunications, software, retail, radio and TV, media, call center and premium rate, technical, advertising, Web portals, monetary intermediation, sponsorship, broadcasting and signal transmission, premises and facilities leasing, and other financial services; produces broadcasting, television, and electronic equipment; produces, leases, and sells set-top boxes; and sells licenses, sublicenses, and property rights, as well as STB hard disk drives, antennas, Internet modems, tablets, laptops, routers, TV sets, accessories, and other devices. The company was formerly known as Polsat Cyfrowy S.A. and changed its name to Cyfrowy Polsat S.A. in 2004. Cyfrowy Polsat S.A. was incorporated in 1996 and is headquartered in Warsaw, Poland.
Full CYFWY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.